# **PROVIDER***Update*





CONTRACTUAL | OCTOBER 17, 2019 | UPDATE 19-796 | 3 PAGES

## Injectable Medication HCPCS/DOFR Crosswalk Reference Table Update – 3rd Quarter 2019

### Approved updates are effective December 23, 2019

On July 16, 2019, the Pharmacy and Therapeutics (P&T) Committee approved updates to the Injectable Medication Healthcare Common Procedure Coding System (HCPCS)/Division of Financial Responsibility (DOFR) Crosswalk.

The approved updates are effective December 23, 2019, and listed on pages 2 and 3. Injectable medications are placed in DOFR categories that mirror the DOFR matrix categories in the Health Net\* and CalViva Health *Provider Participation Agreement (PPA)*.

The update includes:

- 15 new injectable medications and DOFR categories.
- 11 updates and changes to injectable medication procedure codes.

#### Additional information

Relevant sections of the provider operations manuals have been revised to reflect the information contained in this update as applicable. Provider operations manuals are available electronically in the Provider Library, located on the provider website at provider.healthnet.com.

Providers are encouraged to access the provider portal online at provider.healthnet.com for real-time information, including eligibility verification, claims status, prior authorization status, plan summaries, and more.

If you have questions regarding the information contained in this update, contact CalViva Health at 1-888-893-1569.

THIS UPDATE APPLIES TO MEDI-CAL PROVIDERS:

• Physicians

Participating Physician Groups

○ Hospitals

 $^{\odot}$  Ancillary Providers

PROVIDER SERVICES 1-888-893-1569 www.healthnet.com

CalViva Health is a licensed health plan in California that provides services to Medi-Cal enrollees in Fresno, Kings and Madera counties. CalViva Health contracts with Health Net Community Solutions, Inc. to provide and arrange for network services. \*Health Net Community Solutions, Inc. is a subsidiary of Health Net, LLC and Centene Corporation. Health Net is a registered service mark of Health Net, LLC. All other identified trademarks/service marks remain the property of their respective companies. All rights reserved. CONFIDENTIALITY NOTE FOR FAX TRANSMISSION: This facsimile may contain confidential information. The information is intended only for the use of the individual or entity named above. If you are not the intended recipient, or the person responsible for delivering it to the intended recipient, you are hereby notified that any disclosure, copying, distribution, or use of the information contained in this transmission is strictly PROHIBITED. If you have received this transmission in error, please notify the sender immediately by telephone or by return fax and destroy this transmission, along with any attachments. OTH035826EW00 (10/19)

#### Additions to injectable medication HCPCS/DOFR crosswalk

The following medications have been approved by the P&T Committee as additions to the Injectable Medication HCPCS/DOFR Crosswalk Reference Table. P&T Committee members include physicians and representatives from Health Net and CalViva Health participating physician groups (PPGs).

HCPCS	Drug name	Generic name	Primary category	Secondary category
J3590	Ascenvi™	Immune globulin intravenous, human-sira	Therapeutic injection	Home health/infusion
J3590	Cutaquig®	Immune globulin subcutaneous (human)-	Therapeutic injection	Home health/infusion
C9048	Dextenza®	Dexamethasone ophthalmic insert	Therapeutic injection	
J3590	Evenity®	Romosozumab-aqqg injection, for	Therapeutic injection	
Q5113	Herzuma®	Trastuzumab-pkrb, biosimilar, 10	Therapeutic injection	Chemotherapy
C9399, J3590	Infugem™	Gemcitabine in sodium chloride injection,	Therapeutic injection	Chemotherapy
Q5114	Ogivri®	Trastuzumab-dkst, biosimilar, 10	Therapeutic injection	Chemotherapy
Q5112	Ontruzant®	Trastuzumab-dttb, biosimilar, 10	Therapeutic injection	Chemotherapy
J3590, J9999	Polivy™	Polatuzumab vedotin-piiq for intravenous	Therapeutic injection	Chemotherapy
C9399, J3590	Skyrizi™	Rosankizumab-rzaa injection, for	Therapeutic injection	
J1444	Triferic®	Ferric pyrophosphate citrate powder, 0.1	Therapeutic injection	
J3490	Xyosted Inj™	Testosterone enanthate solution auto-	Therapeutic injection	
J3490	Zolgensma®	Onasemnogene abeparvocec-xioi	Therapeutic injection	
J3490	Zulresso™	Brexanolone injection, for intravenous use	Therapeutic injection	
90619	N/A	Meningococcal conjugate vaccine,	Therapeutic injection	Immunizations

#### Updates/changes to injectable medication procedure codes or medications

Updates to the Injectable Medication HCPCS/DOFR Crosswalk Reference Table are based on changes or updates to HCPCS codes or changes in medication descriptions or availability. The following are changes to injectable medications currently listed in the crosswalk.

HCPCS	Drug name	Generic name	Comment
J9036	Belrapzo™	Bendamustine hcl (belrapzo), 1 mg	Replaces C9042
C9047	Cablivi <sup>®</sup>	Caplacizumab-yhdp, 1 mg	Replaces J3590
C9049	Elzonris™	Tagraxofusp-erzs, 10 mcg	Replaces J9999
C9050	Gamifant®	Emapalumab-lzsg, 1 mg	Replaces J3590

Updates, continued						
HCPCS	Drug name	Generic name Comment				
J9355	Hercep	Trastuzumab, excludes biosimilar, 10 mg	New description-replaces X7640			
J7208	Jivi <sup>®</sup>	factor viii, (antihemophilic factor, recombinant),	Replaces C9141			
C9044	Libtayo®	Cemiplimab-Rwlc intravenous Soln	Replaces J9999			
90734	Menactra <sup>®</sup> ,	Meningococcal conjugate vaccine, serogroups A, C, W,	New description			
Q5115	Truxima™	Rituximab-abbs, biosimilar,10 mg	Replaces J9999			
J9031	Theracys®	bCG (intravesical), per installation	Code deleted			
C9052	Ultomiris™	Ravulizumab-cwvz, 10 mg	Replaces J3590			

\*HCPCS codes were taken from the Centers for Medicare & Medicaid Services (CMS) HCPCS website at www.cms.gov/Medicare/Coding/HCPCSReleaseCodeSets/Alpha-Numeric-HCPCS.html.